Anxo Pharmaceutical Co., Ltd.
6677
Rank in Stocks
#24141
Anxo Pharmaceutical Co., Ltd. functions as a specialized enterprise in the... Anxo Pharmaceutical Co., Ltd. functions as a specialized enterprise in the pharmaceutical sector. This company is actively involved in the research, production, and global distribution of various medicinal products, catering to both healthcare professionals and individual patients, particularly within Taiwan and across international markets. Its comprehensive product catalog features both prescription-only drugs and over-the-counter remedies, addressing a broad spectrum of therapeutic needs. These include cardiovascular health, metabolic disorders, conditions affecting the central nervous system, diabetes management, respiratory ailments, anti-infective treatments, dermatological issues, nephrology, urology, and orthopedics, among others. More specifically, Anxo supplies agents for antidiabetic and dyslipidemic conditions, supports cardiovascular and circulatory systems, offers therapies for the nervous system, addresses hepatological and gastroenterological concerns, provides anti-infective and antiviral agents, and assists with hemodialysis and urinary system treatments. Additionally, their offerings cover respiratory system and antihistamine applications, various analgesics, and other specialized medications, including a range of injectable pharmaceuticals. Established in 2003, the company's main operational base is situated in Taipei, Taiwan.
Share Price
$0.63712519
Last synced: 2026-11-10
Market Cap
$35.67M
Change (1 day)
-3.02%
Change (1 year)
-18.06%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Anxo Pharmaceutical Co., Ltd. (6677)
Category
Healthcare
EPS for Anxo Pharmaceutical Co., Ltd. (6677)
EPS as of June 2026 TTM: $-0.01
According to Anxo Pharmaceutical Co., Ltd.'s latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2025 the company had an EPS of $-0.02, an increase over its 2024 EPS of $-0.03.
EPS history for Anxo Pharmaceutical Co., Ltd. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | -43.00% |
| 2025 | $-0.02 | -38.22% |
| 2024 | $-0.03 | -324.29% |
| 2023 | $0.01 | -264.71% |
| 2022 | $-0.01 | -160.28% |
| 2021 | $0.01 | -37.05% |
| 2020 | $0.02 | 28.74% |
| 2019 | $0.02 | -13.43% |
| 2018 | $0.02 | -196.17% |
| 2017 | $-0.02 | 50.36% |
| 2016 | $-0.01 | -10.32% |
| 2015 | $-0.02 | -152.36% |
| 2014 | $0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -57,129.82% |
DE
|
|
| $6.08 | -53,412.28% |
DE
|
|
| $1.55 | -13,701.75% |
JP
|
|
| $3.66 | -32,205.26% |
CH
|
|
| $0.45 | -4,047.37% |
IL
|
Questions about Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS)
What is Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS)?
Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS) over the last twelve months is $-0.01, as of Jun 2026.
What was Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS) was $-0.02, compared with $-0.03 in 2024.
How has Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS) was highest in 2020 ($0.02) and lowest in 2024 ($-0.03).
How does Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS) compare with similar companies?
Anxo Pharmaceutical Co., Ltd.'s earnings per share (EPS) ($-0.01) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.